Matthew Disney

SPARK NS Autism Project

Novel mRNA degraders to target hypoxic tumor microenvironment

Targeted degradation of RNAs by using small molecules

Graduate Research Fellowship program (GRFP)

Small molecule degradation of tau mRNA

Developing Artificial Intelligence and Machine Learning Approaches to Identify and Optimize Small Molecule Medicines Targeting Oncogenic RNAs

Design of small molecules that degrade the mRNA encoding a-synuclein

Brain penetrant small molecules drugs that target tau pre-mRNA for degradation

Development of Clinical Candidates for the Treatment of Myotonic Dystrophy

Targeting the RNA Repeat Expansion that Causes Myotonic Dystrophy Type 2

Astellas Pharma Inc. bench fees for Dr. Ryuichi Sekioka

CD33 Targeting Small Molecule Drug Discovery

Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses

RNA-Targeted Drug Discovery and Development for Parkinson's Disease

Design and evaluation of drug-like small molecules targeting repeat expansion (MDA 963835)

Pathophysiology of genetically defined dementia and neurodegeneration: Defining therapeutic targets and pathways

Targeted degradation of RNAs by using small molecules

Design of precision small molecules targeting RNA repeating transcripts to manipulate and study disease biology

Small Molecules That Target the RNAs That Cause Pulmonary Fibrosis and Polycystic Kidney Disease

Center for Antiviral Medicines & Pandemic Preparedness (CAMPP) - PROJECT 4

Design and Study of Small Molecules That Cleave the RNA That Causes Myotonic Dystrophy Type 1 (DM1)

Pre-clinical evaluation of small molecules that rescue aberrant Tau mRNA splicing

Targeting mRNAs that Contribute to Neurological Disease

Targeting RNAs Associated with Tauopathies with Small Molecules

Expanding Ribonuclease Targeting Chimeras (RIBOTACs) to Advance Targeted Degradation of Disease-Causing RNAs